The MFN policy is directly reshaping how the drug will reach European patients. Eli Lilly CEO David Ricks has stated that the company will still pursue public reimbursement from European governments, but the primary launch route will be via self-pay telehealth platforms — the same direct-to-consumer model used in the U.S. . This marks a fundamental shift: launching first into private cash-pay channels rather than waiting months or years for national reimbursement negotiations.

The mechanism is clear. On August 14, 2025, Eli Lilly raised the UK list price of Mounjaro (tirzepatide) by up to 170% — from £122 to £330 per month for the highest dose — explicitly as a response to Trump administration pressure to lower U.S. prices . By

The MFN policy is directly reshaping how the drug will reach European patients. Eli Lilly CEO David Ricks has stated that the company will still pursue public reimbursement from European governments, but the primary launch route will be via self-pay telehealth platforms — the same direct-to-consumer model used in the U.S. . This marks a fundamental shift: launching first into private cash-pay channels rather than waiting months or years for national reimbursement negotiations.

The mechanism is clear. On August 14, 2025, Eli Lilly raised the UK list price of Mounjaro (tirzepatide) by up to 170% — from £122 to £330 per month for the highest dose — explicitly as a response to Trump administration pressure to lower U.S. prices . By